Merck & Co. MRK Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $65.77B+1.2% | $65.01B+1.2% | $64.24B+1.0% | $63.62B-0.5% | $63.92B-0.4% | ||
| $17.16B+4.7% | $16.38B+11.8% | $14.66B-1.5% | $14.88B-1.2% | $15.07B-0.8% | ||
| $48.61B0.0% | $48.63B-1.9% | $49.58B+1.7% | $48.73B-0.2% | $48.85B-0.3% | ||
| 73.9%-0.9pp | 74.8%-2.4pp | 77.2%+0.6pp | 76.6%+0.2pp | 76.4%+0.1pp | ||
| $24.76B+56.8% | $15.79B-4.2% | $16.49B-9.0% | $18.12B+3.1% | $17.57B-2.1% | ||
| $10.88B+1.4% | $10.73B+0.3% | $10.7B-0.9% | $10.8B-0.8% | $10.89B+0.6% | ||
| $11.63B-44.8% | $21.07B-3.4% | $21.82B+13.9% | $19.16B-5.0% | $20.17B+1.2% | ||
| $2.7B-3.9% | $2.81B+1.2% | $2.77B+1.1% | $2.74B+1.0% | $2.72B-3.0% | ||
| $8.94B-51.1% | $18.25B-4.1% | $19.03B+16.0% | $16.41B-5.9% | $17.43B+1.9% | ||
| 13.6%-14.5pp | 28.1%-1.6pp | 29.6%+3.8pp | 25.8%-1.5pp | 27.3%+0.6pp | ||
| $3.56-51.2% | $7.29-3.7% | $7.57+16.6% | $6.49-5.5% | $6.87+2.1% | ||
| $14.75B-38.8% | $24.11B+0.9% | $23.89B+12.4% | $21.26B-4.5% | $22.26B+1.0% | ||
| 22.4%-14.7pp | 37.1%-0.1pp | 37.2%+3.8pp | 33.4%-1.4pp | 34.8%+0.5pp | ||
| $11.63B-44.8% | $21.07B-3.4% | $21.82B+13.9% | $19.16B-5.0% | $20.17B+1.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Merck & Co.'s revenue?
- Merck & Co. (MRK) generated $65.8B in revenue over the trailing twelve months, up 2.9% year over year.
- Is Merck & Co. profitable?
- Merck & Co. reported $8.9B in net income over the trailing twelve months, a 13.6% net margin.
- What is Merck & Co.'s earnings per share?
- Merck & Co.'s diluted EPS over the trailing twelve months is $3.56.
- Where does Merck & Co.'s income statement data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
